Products

Active product line.

Ceretropic Labs product reaches researchers through regional distribution partners. For purchase inquiries, use the partner listed under each product.

Shipping Q4 2026

GHK-Cu Official

Copper tripeptide research formulation. 50mg lyophilized vial in phosphate-buffered reconstitution solution with phenol preservative and polysorbate stabilizer.

Specifications

CompoundGHK-Cu (Glycyl-Histidyl-Lysine + Cu2+)
CAS89030-95-5
Molecular formulaC14H22CuN6O4
Molecular weight402.84 g/mol
Vial contents50 mg lyophilized powder
Purity≥ 99% (HPLC)
AppearanceBlue crystalline powder (copper complex)
Recommended solventCeretropic Labs reconstitution solution (included)
Post-reconstitution stabilityUp to 42 days refrigerated (2-8°C)
Storage (unopened)Room temperature acceptable up to 30 days; refrigerated for long-term
Lot traceabilityBatch number on every vial links to HPLC chromatogram

Why the formulation differs

Most grey market GHK-Cu ships as powder with bacteriostatic water recommended for reconstitution. That works short-term but creates problems: copper catalyzes slow oxidation of the peptide in neutral pH water, aggregation at the air-liquid interface after repeated vial punctures, and shorter usable post-reconstitution window.

Our formulation uses phosphate buffer at pH 6.5 to hold the peptide at its stability sweet spot, polysorbate 80 to prevent interface aggregation across daily use, and phenol as a preservative with stronger antimicrobial profile than benzyl alcohol. The same approach is used in branded pharmaceutical peptide pens for the same reasons.

Distribution

GHK-Cu Official is distributed in the Serbian market by ghkcu.rs.

Pipeline products

The following compounds are in formulation and QC work. Launch dates are targets, not commitments. Each one goes through the same batch-verification protocol before release.

Q1 2027

Retatrutide

Triple agonist GLP-1/GIP/glucagon compound. 10mg vial with proprietary buffered formulation for extended stability.

Q1 2027

Tirzepatide

Dual GIP/GLP-1 agonist. 10mg vial with the same buffered formulation platform as the GHK-Cu Official launch.

Q2 2027

BPC-157

Pentadecapeptide gastric compound. 5mg vial with phosphate-buffered reconstitution system.

Q2 2027

TB-500

Thymosin Beta-4 full peptide. 10mg vial. Paired with BPC-157 for research applications requiring the classic tissue-repair combination.

Q2 2027

MOTS-c

Mitochondrial-derived peptide. 10mg vial. Pipeline product for metabolic research applications.

Q2 2027

Epithalon

Tetrapeptide from Khavinson research. 20mg vial for extended-cycle research protocols.

Pipeline products are in formulation and QC qualification. Launch dates depend on batch verification outcomes. For distribution partnership inquiries on any pipeline compound, use the contact page.